Coherus Oncology (CHRS) Operating Leases (2019 - 2026)

Coherus Oncology has disclosed Operating Leases across 8 years of filings, most recently posting $459000.0 for Q2 2026.

• In Q2 2026, Operating Leases fell 80.92% year-over-year to $459000.0; the TTM figure through Jun 2026 stood at $459000.0 (down 80.92% YoY), while the FY2025 annual figure was $1.5 million, down 55.66% from the prior year.
• Operating Leases came in at $459000.0 for Q2 2026 at Coherus Oncology, down from $954000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.8 million in Q2 2022 to a low of $459000.0 in Q2 2026.
• Average Operating Leases over 5 years is $3.5 million, with a median of $3.5 million recorded in 2024.
• Year-over-year, Operating Leases soared 160.24% in 2024 and sank 80.92% in 2026.
• Over 5 years, Operating Leases stood at $5.0 million in 2022, then rose by 5.59% to $5.3 million in 2023, then sank by 38.33% to $3.3 million in 2024, then tumbled by 55.66% to $1.5 million in 2025, then sank by 68.5% to $459000.0 in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $459000.0 in Q2 2026, $954000.0 in Q1 2026, and $1.5 million in Q4 2025.